The SciOmics (Single-Cell Integrated Omics) Lab uses high dimension, multi-omic approaches combined with data science to discover and characterize biomarkers associated with cancer patient outcomes. Our lab emphasizes the use of multidisciplinary and creative approaches to dissect the complexities of anti-tumor immune responses and immunotherapy resistance mechanisms, with the goal of translating our findings back into the clinic.
Current Research Project Foci:
The roles of STAT/cytokine signaling pathways in checkpoint immunotherapy. The use of HDAC inhibitors and other epigenetic modifying agents in combination with immunotherapies. Development of new data analysis pipelines and tools. A novel population of T-cells expressing ectoenzymes associated with checkpoint immunotherapy resistance.
Ichikawa J, Yoshida T, Isser A, Laino AS, Vassallo M, Woods D, Kim S, Oelke M, Jones K, Schneck JP, Weber JS. Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells. Clin Cancer Res. 2020 Jul 1;26(13):3384-3396. doi: 10.1158/1078-0432.CCR-19-3487. Epub 2020 Apr 2. PMID: 32241816.
Woods DM, Laino AS, Winters A, Alexandre J, Freeman D, Rao V, Adavani SS, Weber JS, Chattopadhyay PK. Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes. JCI Insight. 2020 Jun 4;5(11):e137066. doi: 10.1172/jci.insight.137066. PMID: 32303612.
Yoshida, T., Ichikawa, J., Giuroiu, I., Laino, A. S., Hao, Y., Krogsgaard, M., Vassallo, M., Woods, D. M., Stephen Hodi, F., & Weber, J. (2020). C reactive protein impairs adaptive immunity in immune cells of patients with melanoma. Journal for immunotherapy of cancer, 8(1), e000234. https://doi.org/10.1136/jitc-2019-000234. PMID: 204799.
Laino, A. S., Woods, D., Vassallo, M., Qian, X., Tang, H., Wind-Rotolo, M., & Weber, J. (2020). Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. Journal for immunotherapy of cancer, 8(1), e000842. https://doi.org/10.1136/jitc-2020-000842. PMID: 32581042.
Laino AS, Betts BC, Veerapathran A, Dolgalev I, Sarnaik A, Quayle SN, Jones SS, Weber JS, Woods DM. HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics. J Immunother Cancer. 2019 Feb 6;7(1):33. doi: 10.1186/s40425-019-0517-0. PMID: 30728070.